Unknown

Dataset Information

0

Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea.


ABSTRACT:

Introduction

Sodium glucose co-transporter 2 (SGLT2) inhibitors, such as dapagliflozin, have demonstrated favorable effects in patients with type 2 diabetes (T2D). However, there are limited reports in the literature regarding the glucose-lowering effects of SGLT2 inhibitors in actual clinical settings.

Methods

The post-marketing surveillance data from a longitudinal prospective study of 2007 patients with T2D who were prescribed dapagliflozin (10 mg/day) were analyzed (ClinicalTrials.gov, NCT02252224).

Results

After 12 weeks of dapagliflozin treatment, glycated hemoglobin (HbA1c) and body mass index were significantly decreased (P < 0.001) from 8.1 ± 1.3% to 7.5 ± 1.2% and from 28.1 ± 4.4 to 27.6 ± 4.2 kg/m2, respectively. Both body weight and HbA1c were reduced in 67.7% of patients, and HbA1c was lowered in 75.1%. Younger age, male sex, shorter diabetes duration, higher baseline HbA1c and estimated glomerular filtration rate (eGFR), and having dapagliflozin as add-on therapy were associated with stronger HbA1c reductions after dapagliflozin use (all P < 0.05). Moreover, subgroup analysis of eGFR of subjects with renal hyperfiltration (eGFR ≥ 120 ml/min/1.73 m2) showed the largest reduction in glucose level (% change, - 9.5; 95% CI - 6.8 to - 12.3 for HbA1c; P < 0.001). Multivariable logistic regression analysis showed that recent T2D diagnosis and higher HbA1c at baseline in patients who received an add-on regimen of dapagliflozin were statistically significantly associated with a dapagliflozin response (all P < 0.05).

Conclusions

Dapagliflozin provides benefits for glycemic control and body weight. Patients in a relatively early stage of the course of diabetes with renal hyperfiltration might be more suitable for and gain maximal benefit from dapagliflozin treatment.

Trial registration

ClinicalTrials.gov identifier, NCT02252224.

Funding

AstraZeneca.

SUBMITTER: Han E 

PROVIDER: S-EPMC6064582 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6598253 | biostudies-literature
| S-EPMC3067240 | biostudies-literature
| S-EPMC4750802 | biostudies-other
| S-EPMC10825567 | biostudies-literature
| S-EPMC8128246 | biostudies-literature
| S-EPMC5719276 | biostudies-literature
| S-EPMC8801662 | biostudies-literature
| S-EPMC7078566 | biostudies-literature
| S-EPMC9316116 | biostudies-literature
| S-EPMC8232726 | biostudies-literature